Brown Advisory Inc. Purchases 38,881 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Brown Advisory Inc. boosted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 679,920 shares of the biotechnology company's stock after buying an additional 38,881 shares during the period. Brown Advisory Inc. owned approximately 1.12% of Blueprint Medicines worth $62,716,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of BPMC. Polar Capital Holdings Plc grew its stake in Blueprint Medicines by 108.0% in the third quarter. Polar Capital Holdings Plc now owns 1,040,000 shares of the biotechnology company's stock valued at $52,229,000 after purchasing an additional 540,000 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in shares of Blueprint Medicines by 22.8% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,685,294 shares of the biotechnology company's stock worth $134,855,000 after acquiring an additional 498,622 shares in the last quarter. Avidity Partners Management LP boosted its stake in shares of Blueprint Medicines by 81.1% during the 3rd quarter. Avidity Partners Management LP now owns 751,600 shares of the biotechnology company's stock worth $37,745,000 after acquiring an additional 336,600 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Blueprint Medicines by 2,788.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 269,658 shares of the biotechnology company's stock worth $24,873,000 after acquiring an additional 260,321 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Blueprint Medicines by 3.2% during the 3rd quarter. Wellington Management Group LLP now owns 5,080,521 shares of the biotechnology company's stock worth $255,144,000 after acquiring an additional 156,807 shares in the last quarter.

Analyst Upgrades and Downgrades

BPMC has been the subject of several recent analyst reports. SVB Leerink upgraded Blueprint Medicines from an "underperform" rating to a "market perform" rating and upped their price target for the stock from $50.00 to $97.00 in a research note on Monday, May 6th. Piper Sandler upped their price target on Blueprint Medicines from $78.00 to $104.00 and gave the stock a "neutral" rating in a research note on Friday, May 3rd. Citigroup upped their price target on Blueprint Medicines from $65.00 to $76.00 and gave the stock a "sell" rating in a research note on Friday, May 3rd. Barclays upped their price target on Blueprint Medicines from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, May 3rd. Finally, Stifel Nicolaus increased their target price on Blueprint Medicines from $120.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, April 26th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Blueprint Medicines currently has an average rating of "Moderate Buy" and a consensus price target of $102.65.

Blueprint Medicines Price Performance

Shares of BPMC traded down $1.68 during mid-day trading on Friday, reaching $104.96. The company had a trading volume of 415,572 shares, compared to its average volume of 732,004. Blueprint Medicines Co. has a twelve month low of $43.89 and a twelve month high of $111.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. The company's 50-day moving average is $94.50 and its 200-day moving average is $84.90. The company has a market capitalization of $6.57 billion, a P/E ratio of -21.82 and a beta of 0.65.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The business had revenue of $71.96 million during the quarter, compared to analysts' expectations of $67.34 million. During the same period in the prior year, the firm posted ($2.65) EPS. Blueprint Medicines's quarterly revenue was up 85.5% compared to the same quarter last year. On average, equities analysts anticipate that Blueprint Medicines Co. will post -5.15 EPS for the current year.

Insider Transactions at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the sale, the director now directly owns 176,050 shares in the company, valued at approximately $15,365,644. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Tracey L. Mccain sold 5,194 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $471,043.86. Following the sale, the executive vice president now directly owns 60,498 shares in the company, valued at approximately $5,486,563.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the sale, the director now owns 176,050 shares in the company, valued at $15,365,644. The disclosure for this sale can be found here. In the last ninety days, insiders sold 104,123 shares of company stock valued at $9,554,679. Corporate insiders own 3.88% of the company's stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.